Magazine Article | September 3, 2018

Companies To Watch: United Neuroscience

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Novel peptide-based vaccines to prevent and treat neurological diseases


United Neuroscience (UNS) is developing vaccines to stimulate the body’s production of “endobodies” against beta-amyloid plaque in Alzheimer’s disease and proteins with causative roles in other diseases. The company engineers its “endobody vaccines” to overcome the body’s natural resistance to mounting immune attacks against endogenous proteins, as traditional vaccines do against foreign pathogens. Its Alzheimer’s vaccine UB-311 is now in Phase 2 clinical trials, and another vaccine, UB-312, is entering clinical trials. A third product, a vaccine targeting tau protein in Alzheimer’s, is in preclinical research. In the preclinical stages are other candidates targeting disease-related neuropeptides and cytokines to treat migraine and several neuroinflammatory indications, neuropathic pain, and neuromuscular dystrophies.